PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9031929-8 1996 CONCLUSION: Since firstly, PGE2 acts through EP1, EP2 and EP3 specific receptors, whereas the action of sulprostone is only mediated by EP1 and EP3, and secondly EP2 receptor is coupled with cAMP production, we conclude that cAMP is involved in mediating the action of PGE2 upon GAG synthesis by human cultured cervical fibroblasts. Dinoprostone 27-31 prostaglandin E receptor 3 Homo sapiens 58-61 9065782-1 1997 Prostaglandin (PG) E2 binds to PGE receptor EP3 subtype and induces Gi activity. Dinoprostone 0-21 prostaglandin E receptor 3 Homo sapiens 44-47 8910368-1 1996 The expression by T lymphocytes (T cells) of more than one of the functionally distinct subtypes of prostaglandin E2 (PGE2) receptors (Rs), designated EP1, EP2, EP3, and EP4 Rs, is a principal determinant of specificity and diversity of the immune effects of PGE2. Dinoprostone 100-116 prostaglandin E receptor 3 Homo sapiens 161-164 9530435-2 1997 PGE2 may interact with at least four receptor subtypes (EP1, EP2, EP3, EP4), each showing different pharmacological profiles. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 66-69 9530435-6 1997 PGE2 increased cAMP level and this effect was shared by the EP2 receptor subtype selective agonist Butaprost and by Misoprostol (EP3 > EP2 > EP1). Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 129-132 8910368-11 1996 Thus, stimulation of MMP-9 in HSB.2 T cells by PGE2 is attributable to [Ca2+]i-dependent EP3 R-mediation of increases in message transcription. Dinoprostone 47-51 prostaglandin E receptor 3 Homo sapiens 89-92 8641211-1 1996 PGE2 is a powerful modulator of uterine contractility, but there is uncertainty as to which receptor subtypes (EP1, EP2, EP3, or EP4), G proteins, and second messenger systems are activated by PGE2 in myometrium. Dinoprostone 193-197 prostaglandin E receptor 3 Homo sapiens 121-124 8906549-2 1996 The effects of PGE2 are exerted by a variety of PGE receptors which are different in their signal transduction properties and are classified into four subtypes, EP1, EP2, EP3 and EP4. Dinoprostone 15-19 prostaglandin E receptor 3 Homo sapiens 171-174 8567030-4 1995 EP3 R expression was demonstrated by inhibition of [3H]PGE2 binding with the EP1/EP3 agonist sulprostone [50% inhibitory concentration (IC50 = 3.3 +/- 0.6 nM)] and the EP3/EP2 agonist M&B 28767 (IC50 = 2.1 +/- 0.3 nM), but not with the EP1 antagonist SC-19220. Dinoprostone 55-59 prostaglandin E receptor 3 Homo sapiens 0-3 8928854-1 1996 Four prostaglandin E2 (PGE2) receptors designated EP1, EP2, EP3, and EP4 have been pharmacologically identified, cloned, and sequenced. Dinoprostone 5-21 prostaglandin E receptor 3 Homo sapiens 60-63 8908618-5 1996 We postulate that the weak platelet response to PGE2 is due to co-localization of a PGE2 receptor that couples to stimulation of adenyl cyclase with the EP3 prostaglandin receptor that binds PGE2 tightly and inhibits adenyl cyclase. Dinoprostone 48-52 prostaglandin E receptor 3 Homo sapiens 153-156 8567030-4 1995 EP3 R expression was demonstrated by inhibition of [3H]PGE2 binding with the EP1/EP3 agonist sulprostone [50% inhibitory concentration (IC50 = 3.3 +/- 0.6 nM)] and the EP3/EP2 agonist M&B 28767 (IC50 = 2.1 +/- 0.3 nM), but not with the EP1 antagonist SC-19220. Dinoprostone 55-59 prostaglandin E receptor 3 Homo sapiens 81-84 8567030-4 1995 EP3 R expression was demonstrated by inhibition of [3H]PGE2 binding with the EP1/EP3 agonist sulprostone [50% inhibitory concentration (IC50 = 3.3 +/- 0.6 nM)] and the EP3/EP2 agonist M&B 28767 (IC50 = 2.1 +/- 0.3 nM), but not with the EP1 antagonist SC-19220. Dinoprostone 55-59 prostaglandin E receptor 3 Homo sapiens 81-84 8567030-5 1995 EP2 R protein was identified by Western blot analysis using specific rabbit IgG antibodies to an amino-terminal peptide of the EP2 R. EP2 R transduced PGE2 stimulation of significant increases in cellular [cAMP]i [50% effective concentration (EC50 = 20 +/- 2.5 nM)], and EP3 R mediated sulprostone inhibition of forskolin elevation of [cAMP]i (IC50 = 1.3 +/- 0.4 nM). Dinoprostone 151-155 prostaglandin E receptor 3 Homo sapiens 271-274 8567030-7 1995 Pretreatment of U937 cells with PGE2 for 1 and 24 hr reduced both the binding affinity and the total number of PGE2 R, by co-ordinate suppression of the EP2 R and EP3 R. Desensitization of EP2 R and EP3 R for 1 hr with PGE2 suppressed subsequent PGE2-evoked chemokinetic responses to PGE2, whereas selective down-regulation of EP2 R alone by PMA for 1 hr had no effects on U937 cell migration. Dinoprostone 32-36 prostaglandin E receptor 3 Homo sapiens 111-117 8567030-7 1995 Pretreatment of U937 cells with PGE2 for 1 and 24 hr reduced both the binding affinity and the total number of PGE2 R, by co-ordinate suppression of the EP2 R and EP3 R. Desensitization of EP2 R and EP3 R for 1 hr with PGE2 suppressed subsequent PGE2-evoked chemokinetic responses to PGE2, whereas selective down-regulation of EP2 R alone by PMA for 1 hr had no effects on U937 cell migration. Dinoprostone 32-36 prostaglandin E receptor 3 Homo sapiens 163-166 7476918-4 1995 Transfection experiments revealed that all the four isoforms show high binding affinities to PGE2, PGE1, and M&B28767, an EP3-specific agonist, whereas their downstream signaling pathways are divergent. Dinoprostone 93-97 prostaglandin E receptor 3 Homo sapiens 126-129 8567030-7 1995 Pretreatment of U937 cells with PGE2 for 1 and 24 hr reduced both the binding affinity and the total number of PGE2 R, by co-ordinate suppression of the EP2 R and EP3 R. Desensitization of EP2 R and EP3 R for 1 hr with PGE2 suppressed subsequent PGE2-evoked chemokinetic responses to PGE2, whereas selective down-regulation of EP2 R alone by PMA for 1 hr had no effects on U937 cell migration. Dinoprostone 32-36 prostaglandin E receptor 3 Homo sapiens 199-202 7476918-11 1995 The present study suggests the presence of the multiple systems of PGE2/EP3 isoforms and leads to the better understanding of its physiological and pathophysiological implications in humans. Dinoprostone 67-71 prostaglandin E receptor 3 Homo sapiens 72-75 7642528-8 1995 In conclusion, we found that the PGE2-induced opening of the housekeeping Cl- channel in the parietal cell involves the EP3 receptor-mediated increase in [Ca2+]i via a pertussis toxin-sensitive GTP-binding protein, resulting in successive production of NO and cGMP. Dinoprostone 33-37 prostaglandin E receptor 3 Homo sapiens 120-123 7532011-2 1995 PGE2 activities the E-type PG receptor subtypes EP1, EP2 and EP3, whereas the PGE2 analogue, sulprostone, binds only to the EP1 and EP3 receptor subtypes. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 61-64 8135729-10 1994 The cloned receptor exhibited the properties of a prostaglandin EP3 subtype, inhibiting forskolin-stimulated cyclic AMP formation in response to prostaglandin E2 (PGE2) and binding PGE2 with high specificity and a Kd of 3.2 nM. Dinoprostone 145-161 prostaglandin E receptor 3 Homo sapiens 64-67 7883006-1 1995 The EP3 receptor for prostaglandin E2 (PGE2) mediates various biological activities such as uterine contraction, inhibition of gastric acid secretion, presynaptic inhibition of neurotransmitter release and potentiation of platelet aggregation. Dinoprostone 39-43 prostaglandin E receptor 3 Homo sapiens 4-7 7883006-2 1995 In an attempt to understand the molecular basis of this diversity of biological function, we cloned full-length cDNAs encoding EP3 receptors for PGE2 from human uterus cDNA libraries. Dinoprostone 145-149 prostaglandin E receptor 3 Homo sapiens 127-130 7883006-8 1995 The binding of [3H]PGE2 is competed with by unlabelled prostaglandins in the order sulprostone (a PGE2-like agonist) approximately PGE2 >> PGF2 alpha > Iloprost (a prostacyclin analogue) > PGD2, which is specific for EP3 receptors. Dinoprostone 19-23 prostaglandin E receptor 3 Homo sapiens 229-232 7981210-5 1994 When stably expressed in CHO cell transfectants, all isoforms exhibited similar EP3-specific binding of [3H]-PGE2 and PGE2 analogs. Dinoprostone 109-113 prostaglandin E receptor 3 Homo sapiens 80-83 7981210-5 1994 When stably expressed in CHO cell transfectants, all isoforms exhibited similar EP3-specific binding of [3H]-PGE2 and PGE2 analogs. Dinoprostone 118-122 prostaglandin E receptor 3 Homo sapiens 80-83 7981210-9 1994 The dual signal transduction pathways and distinctive tissue distribution of isoforms of the EP3 receptor are consistent with its mediation of diverse functions of PGE2. Dinoprostone 164-168 prostaglandin E receptor 3 Homo sapiens 93-96 7834185-2 1994 In 13 of 15 experiments, prostaglandin E2 (PGE2) and sulprostone (a prostanoid EP1/EP3-receptor agonist) contracted isolated rings of human pulmonary artery at low concentrations (> or = 5 and > or = 0.5 nM respectively). Dinoprostone 25-41 prostaglandin E receptor 3 Homo sapiens 83-86 7883006-0 1995 Splice variants of the human EP3 receptor for prostaglandin E2. Dinoprostone 46-62 prostaglandin E receptor 3 Homo sapiens 29-32 7883006-1 1995 The EP3 receptor for prostaglandin E2 (PGE2) mediates various biological activities such as uterine contraction, inhibition of gastric acid secretion, presynaptic inhibition of neurotransmitter release and potentiation of platelet aggregation. Dinoprostone 21-37 prostaglandin E receptor 3 Homo sapiens 4-7 7970215-2 1994 Our previous study revealed the involvement of the EP3 receptor subtype in the PGE2 induced enhancement of the BK response [Brain Res. Dinoprostone 79-83 prostaglandin E receptor 3 Homo sapiens 51-54 8135729-10 1994 The cloned receptor exhibited the properties of a prostaglandin EP3 subtype, inhibiting forskolin-stimulated cyclic AMP formation in response to prostaglandin E2 (PGE2) and binding PGE2 with high specificity and a Kd of 3.2 nM. Dinoprostone 163-167 prostaglandin E receptor 3 Homo sapiens 64-67 8135729-10 1994 The cloned receptor exhibited the properties of a prostaglandin EP3 subtype, inhibiting forskolin-stimulated cyclic AMP formation in response to prostaglandin E2 (PGE2) and binding PGE2 with high specificity and a Kd of 3.2 nM. Dinoprostone 181-185 prostaglandin E receptor 3 Homo sapiens 64-67 8307176-5 1994 The rank order of potency for prostaglandins and related analogs in competition for [3H]PGE2 specific binding to membranes prepared from transfected COS cells was comparable for all three isoforms, and as predicted for the EP3 receptor, with PGE2 = PGE1 >> PGF2 alpha = iloprost > PGD2 >> U46619. Dinoprostone 242-246 prostaglandin E receptor 3 Homo sapiens 223-226 8117308-0 1994 Cloning and expression of the EP3-subtype of human receptors for prostaglandin E2. Dinoprostone 65-81 prostaglandin E receptor 3 Homo sapiens 30-33 8117308-1 1994 Prostaglandin E2 (PGE2) is a potent mediator in many human tissues that is recognized by three distinct subtypes of receptors (Rs), designated EP1, EP2 and EP3. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 156-159 8117308-1 1994 Prostaglandin E2 (PGE2) is a potent mediator in many human tissues that is recognized by three distinct subtypes of receptors (Rs), designated EP1, EP2 and EP3. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 156-159 7690567-2 1993 The binding was completely displaced by M&B 28767, an EP3-selective agonist, but not by EP1- or EP2-selective ligands, indicating that the PGE2 binding site is of the EP3 subtype PGE receptor. Dinoprostone 143-147 prostaglandin E receptor 3 Homo sapiens 58-61 8149238-0 1993 Involvement of EP3 subtype of prostaglandin E receptors in PGE2-induced enhancement of the bradykinin response of nociceptors. Dinoprostone 59-63 prostaglandin E receptor 3 Homo sapiens 15-18 8149238-3 1993 The agonist for EP3 (M&B28767) simulated the PGE2-induced effect but not for EP2 (butaprost). Dinoprostone 49-53 prostaglandin E receptor 3 Homo sapiens 16-19 8250933-1 1993 Prostaglandin E2 (PGE2) is a potent mediator in many human tissues, that is recognized by three distinct subtypes of receptors, designated EP1, EP2 and EP3. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 152-155 8250933-1 1993 Prostaglandin E2 (PGE2) is a potent mediator in many human tissues, that is recognized by three distinct subtypes of receptors, designated EP1, EP2 and EP3. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 152-155 7690567-2 1993 The binding was completely displaced by M&B 28767, an EP3-selective agonist, but not by EP1- or EP2-selective ligands, indicating that the PGE2 binding site is of the EP3 subtype PGE receptor. Dinoprostone 143-147 prostaglandin E receptor 3 Homo sapiens 171-174 15888106-1 2005 OBJECTIVES: Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors, which are divided into four subtypes, EP1, EP2, EP3 and EP4. Dinoprostone 12-28 prostaglandin E receptor 3 Homo sapiens 132-135 8320839-1 1993 Recently, cDNAs for TXA2 and PGE2 (EP3 and EP2) receptors have been cloned and their primary structure elucidated. Dinoprostone 29-33 prostaglandin E receptor 3 Homo sapiens 35-38 8396726-4 1993 The EP3 receptor mediates the diverse physiological actions of PGE2 (ref. Dinoprostone 63-67 prostaglandin E receptor 3 Homo sapiens 4-7 8396726-7 1993 In chromaffin cells, two different second messenger pathways are activated by PGE2 binding to an apparently single EP3 receptor class. Dinoprostone 78-82 prostaglandin E receptor 3 Homo sapiens 115-118 15888106-1 2005 OBJECTIVES: Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors, which are divided into four subtypes, EP1, EP2, EP3 and EP4. Dinoprostone 30-34 prostaglandin E receptor 3 Homo sapiens 132-135 34822808-1 2022 This review article provides an update for the role of prostaglandin E2 receptors (EP1, EP2, EP3 and EP4) in cardiovascular disease. Dinoprostone 55-71 prostaglandin E receptor 3 Homo sapiens 93-96 34514658-11 2021 CONCLUSIONS: While profiling the sputum of allergic patients for novel miR expression patterns, we uncovered an association between miR-3935 and its predicted target gene, the prostaglandin E3 receptor, which might mediate AIT effects through suppression of the PGE2 -PTGER3 axis. Dinoprostone 262-266 prostaglandin E receptor 3 Homo sapiens 268-274 33790113-5 2021 To address this issue, we determined the crystal structures of antagonist-bound EP4 and PGE2-bound EP3. Dinoprostone 88-92 prostaglandin E receptor 3 Homo sapiens 99-102 35450969-1 2022 BACKGROUND: Prostaglandin E2 (PGE2) increases pulmonary vascular permeability by activation of the PGE2 receptor 3 (EP3) which may explain adverse pulmonary effects of the EP1/EP3 receptor agonist sulprostone in patients. Dinoprostone 12-28 prostaglandin E receptor 3 Homo sapiens 116-119 35450969-1 2022 BACKGROUND: Prostaglandin E2 (PGE2) increases pulmonary vascular permeability by activation of the PGE2 receptor 3 (EP3) which may explain adverse pulmonary effects of the EP1/EP3 receptor agonist sulprostone in patients. Dinoprostone 30-34 prostaglandin E receptor 3 Homo sapiens 116-119 34341104-4 2021 The structure revealed a "polar group in"-binding mode of 15mPGD2 contrasting the "polar group out"-binding mode of PGE2 in its receptor EP3. Dinoprostone 116-120 prostaglandin E receptor 3 Homo sapiens 137-140 34423270-1 2021 Elevated islet production of prostaglandin E2 (PGE2), an arachidonic acid metabolite, and expression of prostaglandin E2 receptor subtype EP3 (EP3) are well-known contributors to the beta-cell dysfunction of type 2 diabetes (T2D). Dinoprostone 104-120 prostaglandin E receptor 3 Homo sapiens 143-146 34423270-7 2021 Insulin secretion assays using an EP3-specific antagonist confirmed functionally relevant upregulation of PGE2 production. Dinoprostone 106-110 prostaglandin E receptor 3 Homo sapiens 34-37 35113749-1 2022 PURPOSE: To compare the prostaglandin E2 receptor subtype 3 (EP3) distribution in the lacrimal glands of normals, non-specific dacryoadenitis, and chronic Stevens-Johnson syndrome (SJS) patients. Dinoprostone 24-40 prostaglandin E receptor 3 Homo sapiens 61-64 33790113-6 2021 The EP3-PGE2 complex exhibits an active-like conformation, including outward movement of the cytoplasmic end of transmembrane (TM) 6 relative to the cytoplasmic end of TM6 of the EP4 complex. Dinoprostone 8-12 prostaglandin E receptor 3 Homo sapiens 4-7 31000507-4 2020 To investigate the EP3 function in the human epidermal keratinocytes, we performed ELISA and quantitative reverse transcription polymerase chain reaction, since it is reported that PGE2 suppresses cytokine production via EP3 in human conjunctival epithelium. Dinoprostone 181-185 prostaglandin E receptor 3 Homo sapiens 19-22 32488496-0 2020 Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR). Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 29-32 31000507-4 2020 To investigate the EP3 function in the human epidermal keratinocytes, we performed ELISA and quantitative reverse transcription polymerase chain reaction, since it is reported that PGE2 suppresses cytokine production via EP3 in human conjunctival epithelium. Dinoprostone 181-185 prostaglandin E receptor 3 Homo sapiens 221-224 31000507-7 2020 CONCLUSION: Our findings revealed that in chronic-phase SJS/TEN, EP3 protein was expressed in the eyelid epidermis and was not downregulated, unlike in conjunctival epithelium, and that PGE2 could suppress cytokine production via EP3 in human epidermal keratinocytes. Dinoprostone 186-190 prostaglandin E receptor 3 Homo sapiens 65-68 31000507-7 2020 CONCLUSION: Our findings revealed that in chronic-phase SJS/TEN, EP3 protein was expressed in the eyelid epidermis and was not downregulated, unlike in conjunctival epithelium, and that PGE2 could suppress cytokine production via EP3 in human epidermal keratinocytes. Dinoprostone 186-190 prostaglandin E receptor 3 Homo sapiens 230-233 32580276-1 2020 The aim of this study was to evaluate the prognostic impact of prostaglandin E2 receptor 3 (EP3) receptor expression might have on the two different breast cancer entities: multifocal/multicentric versus unifocal. Dinoprostone 63-79 prostaglandin E receptor 3 Homo sapiens 92-95 32251289-0 2020 mPGES-1/PGE2 promotes the growth of T-ALL cells in vitro and in vivo by regulating the expression of MTDH via the EP3/cAMP/PKA/CREB pathway. Dinoprostone 8-12 prostaglandin E receptor 3 Homo sapiens 114-117 32251289-6 2020 Our results showed that mPGES-1/PGE2 regulates the expression of MTDH through the EP3/cAMP/PKA-CREB pathway in T-ALL cells. Dinoprostone 32-36 prostaglandin E receptor 3 Homo sapiens 82-85 30338939-4 2018 The PGE2 EP3 receptor antagonist L-798106 abrogated the PGE2 stimulatory effect, while EP3 agonist 17-phenyl trinor prostaglandin E2 (17-pt-PGE2) mimicked the effect of PEG2 on TRPM7. Dinoprostone 4-8 prostaglandin E receptor 3 Homo sapiens 9-12 31008497-3 2019 PGE2 binds to 4 different G protein-coupled receptors including prostaglandin E2 receptor subtypes EP1, EP2, EP3 and EP4. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 109-112 30510192-2 2019 Here, we report the crystal structure of human prostaglandin (PG) E receptor subtype EP3 bound to endogenous ligand PGE2 at 2.90 A resolution. Dinoprostone 116-120 prostaglandin E receptor 3 Homo sapiens 85-88 31835815-5 2019 PGE2 regulates multiple functions in various immune cells by binding to the downstream receptors EP1, EP2, EP3, and EP4, and plays an important role in the development of CRC. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 107-110 30835912-9 2019 These results suggest that PGE2 regulates HBEC migration via cooperation of EP2, EP3, and EP4 receptors. Dinoprostone 27-31 prostaglandin E receptor 3 Homo sapiens 81-84 30338939-4 2018 The PGE2 EP3 receptor antagonist L-798106 abrogated the PGE2 stimulatory effect, while EP3 agonist 17-phenyl trinor prostaglandin E2 (17-pt-PGE2) mimicked the effect of PEG2 on TRPM7. Dinoprostone 56-60 prostaglandin E receptor 3 Homo sapiens 9-12 30338939-11 2018 In conclusion, our results demonstrate that PGE2 activates TRPM7 via EP3/PKA signalling pathway, and that PGE2 enhances migration and proliferation of human glioblastoma cells by up-regulation of the TRPM7 channel. Dinoprostone 44-48 prostaglandin E receptor 3 Homo sapiens 69-72 28415726-5 2017 PGE2 binds its bona fide receptor EP3 which by activating SRC family kinases, induces ADAMs activation which, in turn, releases EGFR-ligands from the cell membrane and promotes nEGFR. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 34-37 29891646-5 2018 In vascular smooth muscle cells or aortic segments, PGE2 increased NADPH oxidase expression and activity and reduced mitochondrial membrane potential, effects that were abolished by antagonists of the PGE2 receptors (EP), EP1 and EP3, and by JNK (c-Jun N-terminal kinase) and ERK1/2 (extracellular-signal-regulated kinases 1/2) inhibition. Dinoprostone 52-56 prostaglandin E receptor 3 Homo sapiens 230-233 29956615-4 2018 PGE2 also exhibits a protective effect against acid-induced duodenal damage and indomethacin-induced small intestinal lesions mediated by EP3/EP4 receptors; these effects in the stomach, duodenum, or small intestine are associated functionally with inhibition of gastric contraction (EP1), stimulation of duodenal HCO3 - secretion (EP3/EP4), or suppression of bacterial invasion due to the inhibition of intestinal motility (EP4) as well as stimulation of mucus secretion (EP3/EP4), respectively. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 138-141 29956615-4 2018 PGE2 also exhibits a protective effect against acid-induced duodenal damage and indomethacin-induced small intestinal lesions mediated by EP3/EP4 receptors; these effects in the stomach, duodenum, or small intestine are associated functionally with inhibition of gastric contraction (EP1), stimulation of duodenal HCO3 - secretion (EP3/EP4), or suppression of bacterial invasion due to the inhibition of intestinal motility (EP4) as well as stimulation of mucus secretion (EP3/EP4), respectively. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 332-335 29956615-4 2018 PGE2 also exhibits a protective effect against acid-induced duodenal damage and indomethacin-induced small intestinal lesions mediated by EP3/EP4 receptors; these effects in the stomach, duodenum, or small intestine are associated functionally with inhibition of gastric contraction (EP1), stimulation of duodenal HCO3 - secretion (EP3/EP4), or suppression of bacterial invasion due to the inhibition of intestinal motility (EP4) as well as stimulation of mucus secretion (EP3/EP4), respectively. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 332-335 29416671-1 2018 Background: Prostaglandin E2 (PGE2) receptor 3 (EP3) regulates tumor cell proliferation, migration, and invasion in numerous cancers. Dinoprostone 12-28 prostaglandin E receptor 3 Homo sapiens 48-51 29416671-6 2018 Treated with PGE2 and EP3 antagonist, RL95-2 cells were investigated by MTT, BrdU, and wound healing assay for functional assessment of EP3. Dinoprostone 13-17 prostaglandin E receptor 3 Homo sapiens 136-139 28710231-8 2017 Collectively, these data reveal a novel function of TSC2 and Rheb in the regulation of EP3 expression and cell viability.Implications: Therapeutic targeting of an aberrant PGE2-EP3 signaling axis may have therapeutic benefit for TSC patients and for other mTOR-hyperactive neoplasms. Dinoprostone 172-176 prostaglandin E receptor 3 Homo sapiens 87-90 28710231-8 2017 Collectively, these data reveal a novel function of TSC2 and Rheb in the regulation of EP3 expression and cell viability.Implications: Therapeutic targeting of an aberrant PGE2-EP3 signaling axis may have therapeutic benefit for TSC patients and for other mTOR-hyperactive neoplasms. Dinoprostone 172-176 prostaglandin E receptor 3 Homo sapiens 177-180 29700097-2 2018 Prostaglandin E2 (PGE2) plays a pivotal role in regulating immune balance during early pregnancy, and it can stimulate inflammatory reactions via prostaglandin E2 receptor 3 (EP3). Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 175-178 29700097-2 2018 Prostaglandin E2 (PGE2) plays a pivotal role in regulating immune balance during early pregnancy, and it can stimulate inflammatory reactions via prostaglandin E2 receptor 3 (EP3). Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 175-178 29661238-15 2018 However, the functional aspects of EP3 receptor in breast cancer and the way how EP3 may oppose the pro-tumorigenic effects of PGE2 elevation and COX-2 overexpression are not fully understood so far. Dinoprostone 127-131 prostaglandin E receptor 3 Homo sapiens 81-84 29408043-2 2018 One of these prostanoids, prostaglandin E2 (PGE2), interacts with four different G protein-coupled receptors, named EP1, EP2, EP3 and EP4, to initiate different downstream signalling pathways. Dinoprostone 26-42 prostaglandin E receptor 3 Homo sapiens 126-129 29408043-2 2018 One of these prostanoids, prostaglandin E2 (PGE2), interacts with four different G protein-coupled receptors, named EP1, EP2, EP3 and EP4, to initiate different downstream signalling pathways. Dinoprostone 44-48 prostaglandin E receptor 3 Homo sapiens 126-129 28630103-0 2017 Up-regulation of EP2 and EP3 receptors in human tolerogenic dendritic cells boosts the immunosuppressive activity of PGE2. Dinoprostone 117-121 prostaglandin E receptor 3 Homo sapiens 25-28 28753926-3 2017 Little is known about the expression of the Prostaglandin E receptor type 3 (EP3) or the Prostaglandin (PG)E2-EP3 signalling in cervical cancer, so the aim of the study was to analyse the expression of the EP3 receptor in cervical cancer and find prognostic factors in relation to survival; EP3 immunohistological staining of 250 cervical cancer slides was performed and analysed with a semi-quantitative score. Dinoprostone 89-109 prostaglandin E receptor 3 Homo sapiens 110-113 28753926-3 2017 Little is known about the expression of the Prostaglandin E receptor type 3 (EP3) or the Prostaglandin (PG)E2-EP3 signalling in cervical cancer, so the aim of the study was to analyse the expression of the EP3 receptor in cervical cancer and find prognostic factors in relation to survival; EP3 immunohistological staining of 250 cervical cancer slides was performed and analysed with a semi-quantitative score. Dinoprostone 89-109 prostaglandin E receptor 3 Homo sapiens 110-113 28753926-3 2017 Little is known about the expression of the Prostaglandin E receptor type 3 (EP3) or the Prostaglandin (PG)E2-EP3 signalling in cervical cancer, so the aim of the study was to analyse the expression of the EP3 receptor in cervical cancer and find prognostic factors in relation to survival; EP3 immunohistological staining of 250 cervical cancer slides was performed and analysed with a semi-quantitative score. Dinoprostone 89-109 prostaglandin E receptor 3 Homo sapiens 110-113 28415726-6 2017 Amphiregulin (AREG) and Epiregulin (EREG) appear to be involved in nEGFR promoted by the PGE2/EP3-SRC axis. Dinoprostone 89-93 prostaglandin E receptor 3 Homo sapiens 94-97 28415726-7 2017 Pharmacological inhibition or silencing of the PGE2/EP3/SRC-ADAMs signaling axis or EGFR ligands i.e. AREG and EREG expression abolishes nEGFR induced by PGE2. Dinoprostone 47-51 prostaglandin E receptor 3 Homo sapiens 52-55 28415726-7 2017 Pharmacological inhibition or silencing of the PGE2/EP3/SRC-ADAMs signaling axis or EGFR ligands i.e. AREG and EREG expression abolishes nEGFR induced by PGE2. Dinoprostone 154-158 prostaglandin E receptor 3 Homo sapiens 52-55 28415726-8 2017 In conclusion, PGE2 induces NSCLC cell proliferation by EP3 receptor, SRC-ADAMs activation, EGFR ligands shedding and finally, phosphorylation and nEGFR. Dinoprostone 15-19 prostaglandin E receptor 3 Homo sapiens 56-59 26932930-7 2016 These findings suggest that adipocyte COX-2 PGE2-EP3-mediated signaling is crucially involved in the development of obesity-associated AT inflammation and insulin resistance.-Chan, P.-C., Hsiao, F.-C., Chang, H.-M., Wabitsch, M., Hsieh, P. S. Importance of adipocyte cyclooxygenase-2 and prostaglandin E2-prostaglandin E receptor 3 signaling in the development of obesity-induced adipose tissue inflammation and insulin resistance. Dinoprostone 44-48 prostaglandin E receptor 3 Homo sapiens 49-52 27107947-2 2016 Previously, most EP3 antagonists were large acidic ligands that mimic the substrate, prostaglandin E2 (PGE2). Dinoprostone 85-101 prostaglandin E receptor 3 Homo sapiens 17-20 28065721-0 2017 The key residue within the second extracellular loop of human EP3 involved in selectively turning down PGE2- and retaining PGE1-mediated signaling in live cells. Dinoprostone 103-107 prostaglandin E receptor 3 Homo sapiens 62-65 28065721-3 2017 PGE1 and PGE2 docking into the hEP3 model showed differing configurations within the extracellular ligand recognition site. Dinoprostone 9-13 prostaglandin E receptor 3 Homo sapiens 31-35 28065721-10 2017 Our study provided information that S211L within EP3 is the key residue to distinguish PGE1 and PGE2 binding to mediate diverse biological functions at the initial recognition step. Dinoprostone 96-100 prostaglandin E receptor 3 Homo sapiens 49-52 27107947-2 2016 Previously, most EP3 antagonists were large acidic ligands that mimic the substrate, prostaglandin E2 (PGE2). Dinoprostone 103-107 prostaglandin E receptor 3 Homo sapiens 17-20 25865705-0 2015 Exogenous arachidonic acid mediates permeability of human brain microvessel endothelial cells through prostaglandin E2 activation of EP3 and EP4 receptors. Dinoprostone 102-118 prostaglandin E receptor 3 Homo sapiens 133-136 26607459-6 2015 PGE2 responses in rat and macaque bladders, but not human, were antagonised by the EP3 antagonist CJ24979 (1microM). Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 83-86 25865705-9 2015 The results indicate that ARA increases permeability of HBMEC monolayers likely via increased production of PGE2 which acts upon EP3 and EP4 receptors to mediate permeability. Dinoprostone 108-112 prostaglandin E receptor 3 Homo sapiens 129-132 25865705-14 2015 The mechanism was mediated, in part, through increased prostaglandin E2 production from ARA which acted upon EP3 and EP4 receptors to increase HBMEC monolayer permeability. Dinoprostone 55-71 prostaglandin E receptor 3 Homo sapiens 109-112 26123748-8 2015 PGE2 treatment activated Wnt-beta-catenin signaling through activation of EP3. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 74-77 26535079-1 2015 Prostaglandin E2 (PGE2), a major product of cyclooxygenase, binds to four different prostaglandin E2 receptors (EP1, EP2, EP3, and EP4) which are G-protein coupled transmembrane receptors (GPCRs). Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 122-125 26123748-10 2015 Suppression of the EP3 receptor via TNF-alpha-PGE2 signaling seems to suppress IVD degeneration by controlling the activation of Wnt signaling. Dinoprostone 46-50 prostaglandin E receptor 3 Homo sapiens 19-22 26535079-1 2015 Prostaglandin E2 (PGE2), a major product of cyclooxygenase, binds to four different prostaglandin E2 receptors (EP1, EP2, EP3, and EP4) which are G-protein coupled transmembrane receptors (GPCRs). Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 122-125 25512021-8 2015 The effects of PGE2 were preferentially mediated by receptor subtypes EP2 and EP4; EP1 was partially involved in pro-adipogenic effects, and EP3 was partially involved in anti-osteogenic effects. Dinoprostone 15-19 prostaglandin E receptor 3 Homo sapiens 141-144 26448174-10 2015 Because the PGE2-EP3 pathway suppresses the inflammation of the ocular surface, skin, and respiratory tract, downregulation of PGE2 by nonsteroidal antiinflammatory drugs or acetaminophen might significantly contribute to the onset of CM-SJS/TEN with SOCs. Dinoprostone 12-16 prostaglandin E receptor 3 Homo sapiens 17-20 26448174-10 2015 Because the PGE2-EP3 pathway suppresses the inflammation of the ocular surface, skin, and respiratory tract, downregulation of PGE2 by nonsteroidal antiinflammatory drugs or acetaminophen might significantly contribute to the onset of CM-SJS/TEN with SOCs. Dinoprostone 127-131 prostaglandin E receptor 3 Homo sapiens 17-20 26253311-2 2015 In response to bacterial infection, PGE2 binds to EP3 receptors on a population of GABAergic neurons in the pre-optic area. Dinoprostone 36-40 prostaglandin E receptor 3 Homo sapiens 50-53 26400315-7 2015 In addition, in the myometrium, significantly higher levels of EP3 mRNA were observed in women treated with dinoprostone, independent of their responsiveness. Dinoprostone 108-120 prostaglandin E receptor 3 Homo sapiens 63-66 26400315-8 2015 Dinoprostone-responders presented 3.6-fold higher levels of EP3 mRNA expression than the spontaneous labor group. Dinoprostone 0-12 prostaglandin E receptor 3 Homo sapiens 60-63 26400315-9 2015 Significantly higher levels of EP3 mRNA in the myometrium of the dinoprostone-treated group indicated that dinoprostone may regulate the EP3 gene on the transcriptional level. Dinoprostone 65-77 prostaglandin E receptor 3 Homo sapiens 31-34 26400315-9 2015 Significantly higher levels of EP3 mRNA in the myometrium of the dinoprostone-treated group indicated that dinoprostone may regulate the EP3 gene on the transcriptional level. Dinoprostone 65-77 prostaglandin E receptor 3 Homo sapiens 137-140 26463849-0 2015 The receptor EP3 to PGE2: A rational target to prevent atherothrombosis without inducing bleeding. Dinoprostone 20-24 prostaglandin E receptor 3 Homo sapiens 13-16 26463849-2 2015 Through the activation of its receptor EP3, PGE2 sensitizes platelets to their agonists but also inhibits them through its two other receptors, EP2 and EP4. Dinoprostone 44-48 prostaglandin E receptor 3 Homo sapiens 39-42 26463849-9 2015 In addition, the EP3 blocking drug DG-041 abrogated the potentiating effect of PGE2 in whole human blood but did not prolong bleeding times in volunteers. Dinoprostone 79-83 prostaglandin E receptor 3 Homo sapiens 17-20 26058972-0 2015 Prostaglandin E2 promotes human cholangiocarcinoma cell proliferation, migration and invasion through the upregulation of beta-catenin expression via EP3-4 receptor. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 150-153 26058972-6 2015 The present study was designed to examine the effects of 4-7 isoforms of EP3 in promoting cholangiocarcinoma progression and the mechanisms by which PGE2 increases beta-catenin protein via EP3 receptors. Dinoprostone 149-153 prostaglandin E receptor 3 Homo sapiens 189-192 26058972-8 2015 These findings reveal that PGE2 upregulated the cholangiocarcinoma cell beta-catenin protein through the EP3-4R/Src/EGFR/PI3K/AKT/GSK-3beta pathway. Dinoprostone 27-31 prostaglandin E receptor 3 Homo sapiens 105-108 26058972-9 2015 The present study identified the functions of EP3 and the mechanisms by which PGE2 regulates beta-catenin expression and promoted cholangiocarcinoma cell growth and invasion. Dinoprostone 78-82 prostaglandin E receptor 3 Homo sapiens 46-49 26377664-4 2015 The biological effects of PGE2 are mediated by signalling through four distinct E-type prostanoid (EP) receptors - EP1 , EP2 , EP3 and EP4 . Dinoprostone 26-30 prostaglandin E receptor 3 Homo sapiens 127-130 25292157-4 2015 The stimulatory effect of PGE2 is replicated in part by either the PG receptor EP3 agonist 17-phenyl trinor PGE2 or by the PG receptor FP agonist PGF2alpha Whereas activation of the various PG receptors induces multiple downstream signals, the response to PGE2 was mimicked by activators of protein kinase C, and suppressed by inhibition of protein kinase C but not by inhibition of protein kinase A. Dinoprostone 26-30 prostaglandin E receptor 3 Homo sapiens 79-82 25460827-9 2015 Taken together, these results demonstrate that PGE2 switches from a stimulator to an inhibitor of cell migration following EMT of airway epithelial cells and that this inhibition is mediated by an altered effect of EP2 and EP4 signaling and an apparent loss of the stimulatory effects of EP1 and EP3. Dinoprostone 47-51 prostaglandin E receptor 3 Homo sapiens 296-299 26228833-3 2015 Low concentrations of PGE2 enhance platelet aggregation through the activation of the EP3 receptors, while at high concentrations it attenuates aggregation via the EP4 receptor. Dinoprostone 22-26 prostaglandin E receptor 3 Homo sapiens 86-89 25741449-2 2015 To carry out a descriptive analysis of the expression of the EP3 receptors of PGE2 in different histological grades of OSCC and adjacent normal epithelium. Dinoprostone 78-82 prostaglandin E receptor 3 Homo sapiens 61-64 25155136-5 2014 PGE2 exerts its actions through four G-protein-coupled receptors designated E-prostanoid (EP) receptors EP1, EP2, EP3, and EP4. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 114-117 25396731-1 2014 Prostaglandin E2 (PGE2) is a bioactive lipid mediator that exerts its biological function through interaction with four different subtypes of E-Prostanoid receptor namely EP1, EP2, EP3 and EP4. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 181-184 25396731-1 2014 Prostaglandin E2 (PGE2) is a bioactive lipid mediator that exerts its biological function through interaction with four different subtypes of E-Prostanoid receptor namely EP1, EP2, EP3 and EP4. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 181-184 25096910-1 2014 Prostaglandin E2 (PGE2) has been reported to play critical roles in cell fate decision by interacting with four types of prostanoid receptors such as EP1, EP2, EP3 and EP4. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 160-163 25096910-1 2014 Prostaglandin E2 (PGE2) has been reported to play critical roles in cell fate decision by interacting with four types of prostanoid receptors such as EP1, EP2, EP3 and EP4. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 160-163 25003953-8 2014 PGE2 evokes stimulatory as well as inhibitory effects in a concentration dependent manner in platelets via prostanoid EP3 or EP4 and prostanoid DP1 receptors. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 118-121 23892039-4 2013 [(3)H]PGE2 specifically bound to the membranes of cells expressing zebrafish EP1a, EP1b and EP3 with a Kd of 4.8, 1.8 and 13.6nM, respectively, and [(3)H]PGF2alpha specifically bound to the membranes of cells expressing zebrafish FP1 and FP2, with a Kd of 6.5 and 1.6nM, respectively. Dinoprostone 6-10 prostaglandin E receptor 3 Homo sapiens 92-95 24323317-0 2014 Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Dinoprostone 30-34 prostaglandin E receptor 3 Homo sapiens 13-16 24062570-13 2013 Differential expression of EP3 isoforms may yield different intracellular responses to PGE2 in granulosa cell subpopulations, contributing to the different roles played by granulosa cell subpopulations in the process of ovulation. Dinoprostone 87-91 prostaglandin E receptor 3 Homo sapiens 27-30 23338277-6 2013 Treatment with PGE2 and the E prostanoid 3 (EP3) receptor agonist, sulprostone, resulted in the time-dependent increase in FBP1 protein expression; sulprostone increased the viability of the liver cancer cells. Dinoprostone 15-19 prostaglandin E receptor 3 Homo sapiens 44-47 23904482-2 2013 However, PGE2 also activates EP3 receptors, and the major signaling pathway of the EP3 receptor splice variants uses inhibition of cAMP synthesis via Gi proteins. Dinoprostone 9-13 prostaglandin E receptor 3 Homo sapiens 29-32 23904482-3 2013 This opposite effect raises the intriguing question of whether the Gi-protein-coupled EP3 receptor may counteract the EP2 and EP4 receptor-mediated pronociceptive effects of PGE2. Dinoprostone 174-178 prostaglandin E receptor 3 Homo sapiens 86-89 23904482-7 2013 In isolated dorsal root ganglion neurons, EP3 receptor activation counteracted the sensitizing effect of PGE2, and stimulation of excitatory EP receptors promoted the expression of membrane-associated inhibitory EP3 receptor. Dinoprostone 105-109 prostaglandin E receptor 3 Homo sapiens 42-45 23246486-5 2013 The EP3 agonist sulprostone and the cAMP analog forskolin mimicked and the EP3 siRNA, antagonist L798106 and the PKA inhibitor H89 abrogated the effect of PGE2 on SDF-1 expression. Dinoprostone 155-159 prostaglandin E receptor 3 Homo sapiens 75-78 23766266-0 2013 Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. Dinoprostone 44-48 prostaglandin E receptor 3 Homo sapiens 49-52 24046862-9 2013 Treatment with agonists, antagonists and silencing of the EP receptors by siRNA revealed that EP3 was the most involved in transducing the intracrine effects of PGE2. Dinoprostone 161-165 prostaglandin E receptor 3 Homo sapiens 94-97 23349487-6 2013 We confirmed that the PGE2-to-EP3 signaling pathway was active in islets from confirmed diabetic BTBR mice and human cadaveric donors, with increased EP3 expression, PGE2 production, and function of EP3 agonists and antagonists to modulate cAMP production and GSIS. Dinoprostone 22-26 prostaglandin E receptor 3 Homo sapiens 150-153 23349487-6 2013 We confirmed that the PGE2-to-EP3 signaling pathway was active in islets from confirmed diabetic BTBR mice and human cadaveric donors, with increased EP3 expression, PGE2 production, and function of EP3 agonists and antagonists to modulate cAMP production and GSIS. Dinoprostone 22-26 prostaglandin E receptor 3 Homo sapiens 150-153 22866894-1 2013 EP3 receptor antagonists may provide a new approach to the treatment of atherothrombotic disease by blocking the ability of prostaglandin E2 (PGE2) to promote platelet function acting via EP3 receptors. Dinoprostone 142-146 prostaglandin E receptor 3 Homo sapiens 0-3 23087260-1 2013 Unlike the majority of G protein-coupled receptors, the prostaglandin E(2) (PGE(2)) E-prostanoid 3 (EP3) receptor binds agonist with high affinity that is insensitive to the presence of guanosine 5[prime]-O-(3-thio)triphosphate (GTPgammaS). Dinoprostone 56-76 prostaglandin E receptor 3 Homo sapiens 100-103 22866894-1 2013 EP3 receptor antagonists may provide a new approach to the treatment of atherothrombotic disease by blocking the ability of prostaglandin E2 (PGE2) to promote platelet function acting via EP3 receptors. Dinoprostone 124-140 prostaglandin E receptor 3 Homo sapiens 0-3 22866894-1 2013 EP3 receptor antagonists may provide a new approach to the treatment of atherothrombotic disease by blocking the ability of prostaglandin E2 (PGE2) to promote platelet function acting via EP3 receptors. Dinoprostone 124-140 prostaglandin E receptor 3 Homo sapiens 188-191 22866894-1 2013 EP3 receptor antagonists may provide a new approach to the treatment of atherothrombotic disease by blocking the ability of prostaglandin E2 (PGE2) to promote platelet function acting via EP3 receptors. Dinoprostone 142-146 prostaglandin E receptor 3 Homo sapiens 188-191 22475642-10 2012 CONCLUSIONS: Our results show that in human corneal epithelial cells, PGE2 attenuated the mRNA expression and production of CCL5, CXCL10, and CXCL11 via both EP2 and EP3, and that the mRNA expression and production of CCL20 and IL-6 was attenuated only by EP3. Dinoprostone 70-74 prostaglandin E receptor 3 Homo sapiens 256-259 22475642-0 2012 Prostaglandin E2 suppresses poly I: C-stimulated cytokine production via EP2 and EP3 in immortalized human corneal epithelial cells. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 81-84 21070749-5 2011 We now show that stimulation of HCA-7 cells with PGE2 enhanced the up-regulation of VEGF receptor-1 (VEGFR-1) expression by a mechanism involving EP3 receptor-mediated activation of phosphatidylinositol 3-kinase and the extracellular signal-regulated kinases. Dinoprostone 49-53 prostaglandin E receptor 3 Homo sapiens 146-149 22475642-10 2012 CONCLUSIONS: Our results show that in human corneal epithelial cells, PGE2 attenuated the mRNA expression and production of CCL5, CXCL10, and CXCL11 via both EP2 and EP3, and that the mRNA expression and production of CCL20 and IL-6 was attenuated only by EP3. Dinoprostone 70-74 prostaglandin E receptor 3 Homo sapiens 166-169 21932512-2 2011 PGE2 plays important roles in regulation of fever, inflammatory responses and blood pressure via four functionally antagonistic E-prostanoid (EP) receptors, which are designated as EP1, EP2, EP3 and EP4, respectively. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 191-194 21095237-1 2011 There is evidence that the overall effects of prostaglandin E(2) (PGE(2)) on human platelet function are the consequence of a balance between promotory effects of PGE(2) acting at the EP3 receptor and inhibitory effects acting at the EP4 receptor, with no role for the IP receptor. Dinoprostone 46-64 prostaglandin E receptor 3 Homo sapiens 184-187 21059804-0 2011 Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 97-100 19210337-1 2009 BACKGROUND AND OBJECTIVE: Prostaglandin E(2), which exerts its actions via EP receptors (EP1, EP2, EP3 and EP4), is a bioactive metabolite of arachidonic acid produced by cyclooxygenase-1 and/or cyclooxygenase-2. Dinoprostone 26-44 prostaglandin E receptor 3 Homo sapiens 99-102 20451959-11 2010 Furthermore, the selective EP3 antagonist DG-041 converted all PGE2 nonresponders to full responders. Dinoprostone 63-67 prostaglandin E receptor 3 Homo sapiens 27-30 20451959-15 2010 EP3 antagonism converts platelets of nonresponders to a PGE2-responsive phenotype. Dinoprostone 56-60 prostaglandin E receptor 3 Homo sapiens 0-3 20219142-1 2010 BACKGROUND: The physiological effects of prostaglandin E1 (PGE1) and prostaglandin E2 (PGE2) are mediated by the prostaglandin E receptor subtypes EP1, EP2, EP3, and EP4, and the respective agonists have been purified. Dinoprostone 69-85 prostaglandin E receptor 3 Homo sapiens 157-160 20219142-1 2010 BACKGROUND: The physiological effects of prostaglandin E1 (PGE1) and prostaglandin E2 (PGE2) are mediated by the prostaglandin E receptor subtypes EP1, EP2, EP3, and EP4, and the respective agonists have been purified. Dinoprostone 87-91 prostaglandin E receptor 3 Homo sapiens 157-160 20094648-7 2010 The platelet EP3 receptor for prostaglandin E(2) is an attractive therapeutic target as EP3 antagonists may selectively avert thrombosis over atherosclerotic plaques without affecting bleeding risk. Dinoprostone 30-48 prostaglandin E receptor 3 Homo sapiens 13-16 20094648-7 2010 The platelet EP3 receptor for prostaglandin E(2) is an attractive therapeutic target as EP3 antagonists may selectively avert thrombosis over atherosclerotic plaques without affecting bleeding risk. Dinoprostone 30-48 prostaglandin E receptor 3 Homo sapiens 88-91 20951077-2 2010 COX-2 promotes the release of the pro-inflammatory mediator prostaglandin E2 (PGE2), which acts on its cell surface G protein-coupled receptors EP1, EP2, EP3, and EP4. Dinoprostone 60-76 prostaglandin E receptor 3 Homo sapiens 154-157 20951077-2 2010 COX-2 promotes the release of the pro-inflammatory mediator prostaglandin E2 (PGE2), which acts on its cell surface G protein-coupled receptors EP1, EP2, EP3, and EP4. Dinoprostone 78-82 prostaglandin E receptor 3 Homo sapiens 154-157 20951077-7 2010 The results presented here show that HNSCC tumoral lesions and their derived cell lines constitutively express COX-2 and the EP1, EP2 and EP3 receptors for PGE2. Dinoprostone 156-160 prostaglandin E receptor 3 Homo sapiens 138-141 19843025-2 2010 PGE2 exerts its biological action by binding to specific receptors (EP1, EP2, EP3 and EP4). Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 78-81 21041985-5 2010 Similarly, the protective effect of PGE2 on indomethacin-induced small intestinal damage or DSS-induced colitis was mimicked by EP3/EP4 agonists or EP4 agonists, respectively. Dinoprostone 36-40 prostaglandin E receptor 3 Homo sapiens 128-131 21041985-6 2010 The mechanisms underlying these actions of PGE2 are related to inhibition of stomach contraction (EP1), stimulation of duodenal HCO3- secretion (EP3/EP4), inhibition of small intestinal contraction (EP4), and stimulation of mucus secretion (EP3/EP4) or down-regulation of cytokine secretion in the colon (EP4), respectively. Dinoprostone 43-47 prostaglandin E receptor 3 Homo sapiens 145-148 21041985-6 2010 The mechanisms underlying these actions of PGE2 are related to inhibition of stomach contraction (EP1), stimulation of duodenal HCO3- secretion (EP3/EP4), inhibition of small intestinal contraction (EP4), and stimulation of mucus secretion (EP3/EP4) or down-regulation of cytokine secretion in the colon (EP4), respectively. Dinoprostone 43-47 prostaglandin E receptor 3 Homo sapiens 241-244 19729667-0 2009 Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 40-43 18843255-0 2009 Hypertonicity stimulates PGE2 signaling in the renal medulla by promoting EP3 and EP4 receptor expression. Dinoprostone 25-29 prostaglandin E receptor 3 Homo sapiens 74-77 19212690-5 2009 Application of an EP3 antagonist (ONO-AE3-240) strongly inhibited cell growth in COX-2 and PGE2 high expression cells (Ca9-22) but not in COX-2 and PGE2 low expression cells (HSC4). Dinoprostone 91-95 prostaglandin E receptor 3 Homo sapiens 18-21 19212690-7 2009 Addition of exogenous PGE2 only partly abrogated the growth inhibition, indicating that the anti-proliferative effect via EP3 receptor signaling was not only due to PGE2-dependent but also PGE2-independent mechanisms. Dinoprostone 22-26 prostaglandin E receptor 3 Homo sapiens 122-125 19212690-7 2009 Addition of exogenous PGE2 only partly abrogated the growth inhibition, indicating that the anti-proliferative effect via EP3 receptor signaling was not only due to PGE2-dependent but also PGE2-independent mechanisms. Dinoprostone 165-169 prostaglandin E receptor 3 Homo sapiens 122-125 19212690-7 2009 Addition of exogenous PGE2 only partly abrogated the growth inhibition, indicating that the anti-proliferative effect via EP3 receptor signaling was not only due to PGE2-dependent but also PGE2-independent mechanisms. Dinoprostone 165-169 prostaglandin E receptor 3 Homo sapiens 122-125 18843255-2 2009 Here we found that mRNA expression by the PGE(2)-activated G-protein-coupled receptors, EP3 and EP4 in the renal medulla was decreased by furosemide treatment, a procedure that reduces medullary hypertonicity. Dinoprostone 42-48 prostaglandin E receptor 3 Homo sapiens 88-91 18480467-7 2008 Subsequent experiments revealed that prostaglandin E2, 1-OH prostaglandin E1 (prostaglandin E receptor 4 [PTGER4] agonist) and butaprost (PTGER2 agonist) increase I SC in a concentration-dependent manner, whereas sulprostone (mixed PTGER1 and PTGER3 agonist) produced no change in I SC. Dinoprostone 37-53 prostaglandin E receptor 3 Homo sapiens 243-249 19012178-1 2008 Receptors for prostanoids on platelets include the EP3 receptor for which the natural agonist is the inflammatory mediator prostaglandin E(2) (PGE(2)) produced in atherosclerotic plaques. Dinoprostone 123-141 prostaglandin E receptor 3 Homo sapiens 51-54 18097066-9 2008 Taken together, these data demonstrate that PGE2 can stimulate or inhibit fibroblast proliferation at clinically relevant concentrations, via preferential signaling through EP3 or EP2 receptors, respectively. Dinoprostone 44-48 prostaglandin E receptor 3 Homo sapiens 173-176 19227010-3 2008 One alternative approach to targeting Cox-2 enzyme activity is to block binding of the PGE2 ligand to its prostanoid (EP) receptors, which are designated as EP1, EP2, EP3, and EP4 and are members of a subfamily of G protein coupled receptors (GPCRs). Dinoprostone 87-91 prostaglandin E receptor 3 Homo sapiens 167-170 18652829-0 2008 Involvement of non-conserved residues important for PGE2 binding to the constrained EP3 eLP2 using NMR and site-directed mutagenesis. Dinoprostone 52-56 prostaglandin E receptor 3 Homo sapiens 84-87 18508878-7 2008 The data reported here provide the first evidence supporting a functional role for EP3 receptors in normal urinary bladder function and implicate EP3 as a contributor to bladder overactivity during pathological conditions of enhanced PGE2 production, as reported previously in overactive bladder patients. Dinoprostone 234-238 prostaglandin E receptor 3 Homo sapiens 146-149 18042549-4 2008 PGE(2) stimulated the EP3 subtype receptor, as deduced by abrogation of EP3 Galpha(i) subunit activity through pertussis toxin. Dinoprostone 0-6 prostaglandin E receptor 3 Homo sapiens 22-25 18042549-4 2008 PGE(2) stimulated the EP3 subtype receptor, as deduced by abrogation of EP3 Galpha(i) subunit activity through pertussis toxin. Dinoprostone 0-6 prostaglandin E receptor 3 Homo sapiens 72-75 18097066-8 2008 Conversely, the promitogenic effects of mid-range concentrations of PGE2 were mimicked by the EP3-selective agent, sulprostone, by cAMP reduction, and lost upon inhibition of Gi-mediated signaling with pertussis toxin. Dinoprostone 68-72 prostaglandin E receptor 3 Homo sapiens 94-97 17906615-3 2008 The actions of PGE2 are mediated via four main prostanoid receptors, designated EP1, EP2, EP3 and EP4, based on their different pharmacological properties and secondary messenger pathways. Dinoprostone 15-19 prostaglandin E receptor 3 Homo sapiens 90-93 16357326-11 2006 Thus, while PGE2 activates MCs through EP3 receptors, it also counteracts Fc epsilonRI-mediated eicosanoid production through EP2 receptors and PKA, and blocks cytokine transcription. Dinoprostone 12-16 prostaglandin E receptor 3 Homo sapiens 39-42 17692121-6 2007 PGE2 exerted its action by activating EP3 receptors. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 38-41 17692121-12 2007 These observations suggest that PGE2 binds to EP3 receptors, resulting in the activation of cAMP/PKA signaling pathway and leading to an enhancement of P2X3 homomeric receptor-mediated ATP responses in DRG neurons. Dinoprostone 32-36 prostaglandin E receptor 3 Homo sapiens 46-49 16982695-0 2006 Prostaglandin E2 induces fibroblast growth factor 9 via EP3-dependent protein kinase Cdelta and Elk-1 signaling. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 56-59 16982695-4 2006 We report here that prostaglandin E2 (PGE2) induces expression of FGF-9, which promotes endometriotic stromal cell proliferation, through the EP3 receptor-activated protein kinase Cdelta (PKCdelta) signaling pathway. Dinoprostone 20-36 prostaglandin E receptor 3 Homo sapiens 142-145 16982695-4 2006 We report here that prostaglandin E2 (PGE2) induces expression of FGF-9, which promotes endometriotic stromal cell proliferation, through the EP3 receptor-activated protein kinase Cdelta (PKCdelta) signaling pathway. Dinoprostone 38-42 prostaglandin E receptor 3 Homo sapiens 142-145 16982695-7 2006 Collectively, we demonstrate, for the first time, that PGE2 can directly induce FGF-9 expression via a novel signaling pathway involving EP3, PKCdelta, and a member of the ETS domain-containing transcription factor superfamily in primary human endometriotic stromal cells. Dinoprostone 55-59 prostaglandin E receptor 3 Homo sapiens 137-140 16784723-6 2006 Anti-prostaglandin E2 (PGE2) antiserum or antisense oligonucleotides against PGE2 receptor EP2 or EP3 abrogated inhibitory effects of ketoconazole and terbinafine hydrochloride on TNF-alpha-induced NF-kappaB activity and CCL27, CCL2, and CCL5 production, indicating the involvement of endogenous PGE2 in the inhibitory effects. Dinoprostone 5-21 prostaglandin E receptor 3 Homo sapiens 98-101 16784723-6 2006 Anti-prostaglandin E2 (PGE2) antiserum or antisense oligonucleotides against PGE2 receptor EP2 or EP3 abrogated inhibitory effects of ketoconazole and terbinafine hydrochloride on TNF-alpha-induced NF-kappaB activity and CCL27, CCL2, and CCL5 production, indicating the involvement of endogenous PGE2 in the inhibitory effects. Dinoprostone 23-27 prostaglandin E receptor 3 Homo sapiens 98-101 16357326-6 2006 An EP3 receptor-selective agonist, AE-248, mimicked PGE2-mediated ERK phosphorylation, exocytosis, and eicosanoid formation. Dinoprostone 52-56 prostaglandin E receptor 3 Homo sapiens 3-6 17021176-5 2006 Increased activation of EP2 and decreased activation of EP3 by PGE2 synergistically induce an increase in cAMP level, which may induce LTP. Dinoprostone 63-67 prostaglandin E receptor 3 Homo sapiens 56-59 16300797-4 2006 In the cells expressing hEP3I, which is known to produce both a decrease in cAMP and a modest increase in intracellular Ca2+, acid extrusion was gradually accelerated by prostaglandin E2 and reached a plateau at around 2 min. Dinoprostone 170-186 prostaglandin E receptor 3 Homo sapiens 24-29 16300797-7 2006 Pretreatment with pertussis toxin inhibited the response to prostaglandin E2 in hEP3I cells, but the responses in hEP1 and hEP2 cells were not affected. Dinoprostone 60-76 prostaglandin E receptor 3 Homo sapiens 80-85 16300797-8 2006 Na+/H+ exchanger (NHE) inhibitors (EIPA and HOE642) suppressed all the responses induced by prostaglandin E2 in hEP1, hEP2, and hEP3I cells. Dinoprostone 92-108 prostaglandin E receptor 3 Homo sapiens 128-132 16512814-9 2006 CONCLUSIONS: The present results suggest that PGE2 potentiates the IgE-mediated histamine release from the cultured mast cell via EP3 and/or EP1 receptors. Dinoprostone 46-50 prostaglandin E receptor 3 Homo sapiens 130-133 15948687-1 2005 BACKGROUND: Prostaglandin E2 (PGE2), which exerts its actions via EP receptors (EP1, EP2, EP3, and EP4), is a bioactive metabolite produced by cyclooxygenase (COX)-1 and/or COX-2 from arachidonic acid. Dinoprostone 12-28 prostaglandin E receptor 3 Homo sapiens 90-93 16483565-4 2006 Prostaglandin E2 produces a raft of anti-inflammatory effects within the airways, principally through the activation of the prostanoid EP2 and EP3 receptor subtypes. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 143-146 16405508-8 2006 Our data suggest that PGE2 signaling in the brain may be altered after IL-1beta release due to up-regulation of EP3 receptors. Dinoprostone 22-26 prostaglandin E receptor 3 Homo sapiens 112-115 16081678-0 2005 Prostaglandin E2 enhances neurotrophin-4 production via EP3 receptor in human keratinocytes. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 56-59 16188227-0 2005 Rho-kinase mediates spinal nitric oxide formation by prostaglandin E2 via EP3 subtype. Dinoprostone 53-69 prostaglandin E receptor 3 Homo sapiens 74-77 16188227-8 2005 These results suggest that PGE2 stimulates NO formation by Rho-kinase via EP3, a mechanism(s) different from EP1 and EP4. Dinoprostone 27-31 prostaglandin E receptor 3 Homo sapiens 74-77 16262658-5 2005 Low concentrations (1 microm) of PGE2, butaprost (EP2 agonist), and 1-hydroxy-PGE1 (EP4/EP3 agonist) were neuroprotective against Abeta1-42 toxicity, while sulprostone (EP3/EP1 agonist) at similar doses had no detectable effects. Dinoprostone 33-37 prostaglandin E receptor 3 Homo sapiens 169-172 16081678-10 2005 These results suggest that PGE(2) enhances neurotrophin-4 production by activating Sp1 via the EP3/phosphatidylinositol-specific phospholipase C/protein kinase Calpha/MEK1/ERK pathway. Dinoprostone 27-33 prostaglandin E receptor 3 Homo sapiens 95-98 15948687-1 2005 BACKGROUND: Prostaglandin E2 (PGE2), which exerts its actions via EP receptors (EP1, EP2, EP3, and EP4), is a bioactive metabolite produced by cyclooxygenase (COX)-1 and/or COX-2 from arachidonic acid. Dinoprostone 30-34 prostaglandin E receptor 3 Homo sapiens 90-93 29539150-1 2005 BACKGROUND: Prostaglandin E2 (PGE2 ), which exerts its actions via EP receptors (EP1 , EP2 , EP3 , and EP4 ), is a bioactive metabolite produced by cyclooxygenase (COX)-1 and/or COX-2 from arachidonic acid. Dinoprostone 12-28 prostaglandin E receptor 3 Homo sapiens 93-96 15577845-0 2004 Prostaglandin E(2) suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes. Dinoprostone 0-18 prostaglandin E receptor 3 Homo sapiens 63-66 29539150-1 2005 BACKGROUND: Prostaglandin E2 (PGE2 ), which exerts its actions via EP receptors (EP1 , EP2 , EP3 , and EP4 ), is a bioactive metabolite produced by cyclooxygenase (COX)-1 and/or COX-2 from arachidonic acid. Dinoprostone 30-34 prostaglandin E receptor 3 Homo sapiens 93-96 15722440-2 2005 PGE2 can elicit diverse actions within the uterus depending on the PGE2 receptors (EP1, EP2, EP3 and EP4) expressed. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 93-96 15304361-4 2004 Upon prostaglandin E(2) stimulation, EP3.I internalized almost completely, EP3.II, EP3.V, EP3.VI and EP3.f internalized to a lesser extent and EP3.III and EP3.IV did not internalize. Dinoprostone 5-23 prostaglandin E receptor 3 Homo sapiens 37-42 15528329-0 2004 Mechanism of prostaglandin (PG)E2-induced prolactin expression in human T cells: cooperation of two PGE2 receptor subtypes, E-prostanoid (EP) 3 and EP4, via calcium- and cyclic adenosine 5"-monophosphate-mediated signaling pathways. Dinoprostone 13-33 prostaglandin E receptor 3 Homo sapiens 124-143 15331179-7 2004 These results indicate that PGE2-dependent activation of Src signaling via EP3 plays an important role in growth of A549 cells. Dinoprostone 28-32 prostaglandin E receptor 3 Homo sapiens 75-78 15331179-0 2004 Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 73-76 15331179-3 2004 In line with our previous study, here we investigated if Src signaling could be involved in PGE2-stimulated growth of A549 cells via EP3. Dinoprostone 92-96 prostaglandin E receptor 3 Homo sapiens 133-136 15331179-5 2004 A specific antagonist against EP3 abrogated the cell growth and Src activation in the cells stimulated with PGE2. Dinoprostone 108-112 prostaglandin E receptor 3 Homo sapiens 30-33 15304361-4 2004 Upon prostaglandin E(2) stimulation, EP3.I internalized almost completely, EP3.II, EP3.V, EP3.VI and EP3.f internalized to a lesser extent and EP3.III and EP3.IV did not internalize. Dinoprostone 5-23 prostaglandin E receptor 3 Homo sapiens 37-40 15290741-9 2004 CONCLUSION: Mature human osteoclasts present 2 subtypes of EP receptors, namely EP3 and EP4, that mediate different actions of PGE2 on these cells: activation of the EP4 receptors inhibits actin ring formation and activation of the EP3 receptors increases the number of lamellipodia. Dinoprostone 127-131 prostaglandin E receptor 3 Homo sapiens 80-83 15293276-8 2004 Taken together, these data demonstrate an unexpected neuroprotective effect mediated by PGE2, in which activation of its EP2 and EP3 receptors protected motor neurons from chronic glutamate toxicity. Dinoprostone 88-92 prostaglandin E receptor 3 Homo sapiens 129-132 15140225-5 2004 Treatment of melanocytes with EP1 and EP3 receptor agonists resulted in increased melanocyte dendricity, indicating that both EP1 and EP3 receptor signaling contribute to PGE(2)-mediated melanocyte dendricity. Dinoprostone 171-177 prostaglandin E receptor 3 Homo sapiens 38-41 15140225-5 2004 Treatment of melanocytes with EP1 and EP3 receptor agonists resulted in increased melanocyte dendricity, indicating that both EP1 and EP3 receptor signaling contribute to PGE(2)-mediated melanocyte dendricity. Dinoprostone 171-177 prostaglandin E receptor 3 Homo sapiens 134-137 15287155-4 2004 We showed that MCF-7 cells expressed EP2, EP3 and EP4 receptors for PGE2 and that its action was probably mediated by EP4 receptor and adenylyl cyclase activation while cAMP dependent PKA was not involved in the process of inhibition of MMP-9 production. Dinoprostone 68-72 prostaglandin E receptor 3 Homo sapiens 42-45 11997037-0 2002 Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 98-101 14981131-1 2004 Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors (EP1, EP2, EP3, and EP4). Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 82-85 14751245-1 2004 Prostaglandin E(2) (PGE(2)), a major cyclooxygenase (COX-2) metabolite, plays important roles in tumor biology and its functions are mediated through one or more of its receptors EP1, EP2, EP3, and EP4. Dinoprostone 0-18 prostaglandin E receptor 3 Homo sapiens 189-192 14715958-4 2004 PGE2 exerts its downstream effects by signaling through a class of four distinct G-protein-coupled EP receptors (for E-prostanoid: EP1, EP2, EP3, and EP4) that have divergent effects on cAMP and phosphoinositol turnover and different anatomical distributions in brain. Dinoprostone 0-4 prostaglandin E receptor 3 Homo sapiens 141-144 14607240-4 2003 Prostaglandin E(2) (PGE(2)) receptors comprise of four subtypes, EP1, EP2, EP3 and EP4. Dinoprostone 0-18 prostaglandin E receptor 3 Homo sapiens 75-78 12821538-4 2003 Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. Dinoprostone 91-107 prostaglandin E receptor 3 Homo sapiens 138-150 12821538-4 2003 Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. Dinoprostone 91-107 prostaglandin E receptor 3 Homo sapiens 152-155 11997037-3 2002 An antagonistic effect of EP3 against EP4 through the modulation of cyclic AMP level is required for PGE2-mediated activation of Ras signal pathway in A549 cells. Dinoprostone 101-105 prostaglandin E receptor 3 Homo sapiens 26-29 11997037-4 2002 These results suggest that the expression of EP3 may be a critical factor for the PGE2-mediated activation of Ras signal pathway in A549 cells. Dinoprostone 82-86 prostaglandin E receptor 3 Homo sapiens 45-48 14981131-1 2004 Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors (EP1, EP2, EP3, and EP4). Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 82-85 14499627-2 2003 Four subtypes of cell surface receptors (EP1, EP2, EP3, and EP4), which are coupled with different G-proteins, mediate PGE2 actions. Dinoprostone 119-123 prostaglandin E receptor 3 Homo sapiens 51-54 11997037-1 2002 Prostaglandin E2 (PGE2)-dependent effects on various cell responses are regulated by respective PGE2 receptors (EP1, EP2, EP3, EP4) expressing in target cells. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 122-125 11997037-1 2002 Prostaglandin E2 (PGE2)-dependent effects on various cell responses are regulated by respective PGE2 receptors (EP1, EP2, EP3, EP4) expressing in target cells. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 122-125 11842936-1 2002 Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors, which are divided into four subtypes of EP1, EP2, EP3 and EP4. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 122-125 11999132-1 2002 Prostaglandins such as prostaglandin E2 (PGE2) interact with EP-class prostanoid receptors including EP1, EP2, EP3 and EP4 subtypes. Dinoprostone 23-39 prostaglandin E receptor 3 Homo sapiens 111-114 11999132-1 2002 Prostaglandins such as prostaglandin E2 (PGE2) interact with EP-class prostanoid receptors including EP1, EP2, EP3 and EP4 subtypes. Dinoprostone 41-45 prostaglandin E receptor 3 Homo sapiens 111-114 11842936-1 2002 Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors, which are divided into four subtypes of EP1, EP2, EP3 and EP4. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 122-125 11447018-6 2001 Treatment with the EP1, EP2, EP3, and EP4 agonist PGE2 (1 microM) elevated R twofold and significantly increased tissue cAMP content, whereas the EP2 and EP4 agonist deoxy-PGE1 (1 microM) or the EP1 and EP3 agonist sulprostone (1 microM) had no effect. Dinoprostone 50-54 prostaglandin E receptor 3 Homo sapiens 203-206 11095474-2 2000 In the present study, to investigate other functions of PGE2 in human uterus, two EP3 isoforms were isolated by the RT-PCR method using human uterus polyadenylated ribonucleic acid (RNA). Dinoprostone 56-60 prostaglandin E receptor 3 Homo sapiens 82-85 11201045-1 2000 Prostaglandin E2 (PGE2), which exerts its actions via EP receptors (EP1, EP2, EP3, and EP4), is a bioactive metabolite of arachidonic acid produced by cyclooxygenase (COX)-1 and/or COX-2. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 78-81 11201045-1 2000 Prostaglandin E2 (PGE2), which exerts its actions via EP receptors (EP1, EP2, EP3, and EP4), is a bioactive metabolite of arachidonic acid produced by cyclooxygenase (COX)-1 and/or COX-2. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 78-81 11095474-5 2000 The dissociation constant values of EP3-V and EP3-VI for PGE2 were 3.9 and 1.4 nmol/L, respectively, which were consistent with those of previously reported EP3 isoforms. Dinoprostone 57-61 prostaglandin E receptor 3 Homo sapiens 36-52 11095474-5 2000 The dissociation constant values of EP3-V and EP3-VI for PGE2 were 3.9 and 1.4 nmol/L, respectively, which were consistent with those of previously reported EP3 isoforms. Dinoprostone 57-61 prostaglandin E receptor 3 Homo sapiens 36-39 10477136-1 1999 Four prostaglandin E2 receptor subtypes designated EP1, EP2, EP3, and EP4 have been shown to mediate a variety of effects of prostaglandin E2 (PGE2) on glomerular hemodynamics, tubular salt and water reabsorption, and on blood vessels in the human kidney. Dinoprostone 5-21 prostaglandin E receptor 3 Homo sapiens 61-64 10697805-1 1999 Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors, which are divided into 4 subtypes of EP1, EP2, EP3 and EP4. Dinoprostone 0-16 prostaglandin E receptor 3 Homo sapiens 119-122 10697805-1 1999 Prostaglandin E2 (PGE2) exerts its biological actions via EP receptors, which are divided into 4 subtypes of EP1, EP2, EP3 and EP4. Dinoprostone 18-22 prostaglandin E receptor 3 Homo sapiens 119-122 10477136-1 1999 Four prostaglandin E2 receptor subtypes designated EP1, EP2, EP3, and EP4 have been shown to mediate a variety of effects of prostaglandin E2 (PGE2) on glomerular hemodynamics, tubular salt and water reabsorption, and on blood vessels in the human kidney. Dinoprostone 143-147 prostaglandin E receptor 3 Homo sapiens 61-64 9732406-2 1998 EP3 Rs have previously been demonstrated to transduce PGE2 stimulation of secretion of matrix metalloproteinase (MMP)-9 by HSB.2 T cells through Ca++-dependent enhancement of MMP-9 mRNA transcription. Dinoprostone 54-58 prostaglandin E receptor 3 Homo sapiens 0-3 9732406-9 1998 The increased ratio of EP4 Rs/EP3 Rs may contribute to Con A enhancement of PGE2-elicited increases in IL-6 secretion by HSB.2 T cells. Dinoprostone 76-80 prostaglandin E receptor 3 Homo sapiens 30-33 9929561-8 1999 We conclude that ADH stimulates transepithelial Na+ transport by increasing cellular cAMP levels, whereas PGE2 inhibits ADH-dependent Na+ transport by activating EP3-type receptors, which decrease cellular cAMP levels. Dinoprostone 106-110 prostaglandin E receptor 3 Homo sapiens 162-165 9736261-6 1998 EP3 receptor activation also may contribute to PGE2-mediated inhibition of NaCl absorption in the mTAL. Dinoprostone 47-51 prostaglandin E receptor 3 Homo sapiens 0-3 9271782-1 1997 Prostaglandin (PG) E2 binds to four PGE receptor subtypes, EP1, EP2, EP3 and EP4, and induces a variety of functions through the interaction of carboxylic acid of PGE2 and Arg residue in the seventh transmembrane domain of the receptor. Dinoprostone 0-21 prostaglandin E receptor 3 Homo sapiens 69-72 9325177-2 1997 Myometrial contraction by these prostanoids is mediated mainly through EP3 and FP, which are specific receptors to PGE2 and PGF2 alpha, respectively. Dinoprostone 115-119 prostaglandin E receptor 3 Homo sapiens 71-74 9214685-6 1997 The stimulation of cyclic AMP in ODMCl-2 cells by PGE2 and 11-deoxy PGE1, the respective EP1/EP2/EP3/EP4 and EP2/EP3/EP4 receptor agonists, was concentration-dependently inhibited by the EP4 receptor-selective antagonist AH23848. Dinoprostone 50-54 prostaglandin E receptor 3 Homo sapiens 97-100 9153190-1 1997 The prostaglandin EP3 receptor binds Prostaglandin E2 in a ligand binding pocket formed in part by seven transmembrane alpha-helices. Dinoprostone 37-53 prostaglandin E receptor 3 Homo sapiens 18-21 9214685-6 1997 The stimulation of cyclic AMP in ODMCl-2 cells by PGE2 and 11-deoxy PGE1, the respective EP1/EP2/EP3/EP4 and EP2/EP3/EP4 receptor agonists, was concentration-dependently inhibited by the EP4 receptor-selective antagonist AH23848. Dinoprostone 50-54 prostaglandin E receptor 3 Homo sapiens 113-129